ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,930.85
1.09%
US Tech 100
20,836.00
1.31%
Dow Jones
42,840.26
1.18%
Brent Oil
72.72
0.00%
Bitcoin
96,912.80
-0.30%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. AMEX

  6. AEON Biopharma Inc (AEON) Quote

AEON Biopharma Inc

AEON Biopharma Inc (AEON)

AMEX
0.65
0.0005
(0.08%)
Closed December 21 4:00PM
Delayed by 15 minutes
0.6302
-0.0198
(-3.05%)
After Hours: 7:59PM
Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Premium

Key stats and details

Current Price
0.65
Bid
-
Ask
-
Volume
155,577
0.58 Day's Range 0.64
0.5206 52 Week Range 17.17
Market Cap
25.981M
Previous Close
0.6495
Open
0.63
Last Trade
7933
@
0.65
Last Trade Time
Financial Volume
$ 96,217
VWAP
0.618451
Average Volume (3m)
203,580
Shares Outstanding
39,970,693
Dividend Yield
-
PE Ratio
1.05
Earnings Per Share (EPS)
0.6
Revenue
52.75M
Net Profit
24.05M

About AEON Biopharma Inc

AEON Biopharma, Inc. is a bio-pharmaceutical company. The Company is focused on developing ABP-450 (prabotulinumtoxinA) injection for the treatment of debilitating medical conditions with an initial focus on the neurology and gastroenterology markets. ABP-450 contains a 900 kDa botulinum toxin type-... AEON Biopharma, Inc. is a bio-pharmaceutical company. The Company is focused on developing ABP-450 (prabotulinumtoxinA) injection for the treatment of debilitating medical conditions with an initial focus on the neurology and gastroenterology markets. ABP-450 contains a 900 kDa botulinum toxin type-A complex produced by the bacterium clostridium botulinum. The active part of the botulinum toxin is the 150 kDa component, and the remaining 750 kDa of the complex is made up of accessory proteins. When injected at therapeutic levels, ABP-450 blocks peripheral acetylcholine release at presynaptic cholinergic nerve terminals by cleaving SNAP-25, a protein integral to the docking and release of acetylcholine from vesicles situated within the nerve endings leading to denervation and relaxation of the muscle. It is also engaged in the Phase II clinical study of ABP-450 for the treatment of cervical dystonia. Cervical dystonia, also known as spasmodic torticollis, is a neurological condition. Show more

Sector
Pharmaceutical Preparations
Industry
Blank Checks
Headquarters
Wilmington, Delaware, USA
Founded
2022
AEON Biopharma Inc is listed in the Pharmaceutical Preparations sector of the American Stock Exchange with ticker AEON. The last closing price for AEON Biopharma was $0.65. Over the last year, AEON Biopharma shares have traded in a share price range of $ 0.5206 to $ 17.17.

AEON Biopharma currently has 39,970,693 shares outstanding. The market capitalization of AEON Biopharma is $25.96 million. AEON Biopharma has a price to earnings ratio (PE ratio) of 1.05.

Ask ADVFN Intelligence (AI)

AEON Latest News

More News

Form 8-K - Current report

December 20 2024
Edgar (US Regulatory)

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

November 14 2024
Edgar (US Regulatory)

Form 424B3 - Prospectus [Rule 424(b)(3)]

November 13 2024
Edgar (US Regulatory)

Form 8-K - Current report

November 13 2024
Edgar (US Regulatory)

Form 8-K - Current report

October 07 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

September 04 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

September 04 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

September 04 2024
Edgar (US Regulatory)

Form EFFECT - Notice of Effectiveness

August 22 2024
Edgar (US Regulatory)

Form 424B5 - Prospectus [Rule 424(b)(5)]

August 21 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.0611-8.592321755030.71110.7497990.61310310.65366931CS
40.09116.27906976740.5590.90.52062971080.68467827CS
12-0.2358-26.62000451570.88581.60510.52062035800.86306421CS
26-0.72-52.55474452551.373.740.52069445012.26185822CS
52-5.46-89.36170212776.1117.170.52065123422.52248141CS
156-9.49-93.589743589710.1417.170.52063829952.72744055CS
260-9.49-93.589743589710.1417.170.52063829952.72744055CS

AEON - Frequently Asked Questions (FAQ)

What is the current AEON Biopharma share price?
The current share price of AEON Biopharma is $ 0.65
How many AEON Biopharma shares are in issue?
AEON Biopharma has 39,970,693 shares in issue
What is the market cap of AEON Biopharma?
The market capitalisation of AEON Biopharma is USD 25.96M
What is the 1 year trading range for AEON Biopharma share price?
AEON Biopharma has traded in the range of $ 0.5206 to $ 17.17 during the past year
What is the PE ratio of AEON Biopharma?
The price to earnings ratio of AEON Biopharma is 1.05
What is the cash to sales ratio of AEON Biopharma?
The cash to sales ratio of AEON Biopharma is 0.48
What is the reporting currency for AEON Biopharma?
AEON Biopharma reports financial results in USD
What is the latest annual turnover for AEON Biopharma?
The latest annual turnover of AEON Biopharma is USD 52.75M
What is the latest annual profit for AEON Biopharma?
The latest annual profit of AEON Biopharma is USD 24.05M
What is the registered address of AEON Biopharma?
The registered address for AEON Biopharma is CORPORATION TRUST CENTER, 1209 ORANGE ST, NEW CASTLE, WILMINGTON, DELAWARE, 19801
Which industry sector does AEON Biopharma operate in?
AEON Biopharma operates in the BLANK CHECKS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
MGLDMarygold Companies Inc
$ 2.053
(48.77%)
128.45k
MINFT Limited
$ 7.25
(44.22%)
948.53k
CTMCastellum Inc
$ 0.578
(41.01%)
8.88M
KULRKULR Technology Group Inc
$ 2.885
(28.79%)
75.32M
MSTUT Rex 2X Long MSTR Daily Target ETF
$ 12.49
(22.81%)
64.47M
BATLBattalion Oil Corporation
$ 1.3499
(-44.56%)
1.63M
NVOXDefiance Daily Target 2x Long Nvo ETF
$ 11.5991
(-35.47%)
407.1k
UVIX2x Long VIX Futures ETF
$ 3.83
(-29.07%)
70.61M
TPETTrio Petroleum Corp
$ 1.10
(-25.17%)
2.81M
MSTZT Rex 2X Inverse MSTR Daily Target ETF
$ 19.235
(-23.06%)
21.33M
SPYSPDR S&P 500
$ 591.15
(0.86%)
121.43M
SPXSDirexion Daily S&P 500 Bear 3X Shares New
$ 6.1628
(-3.25%)
114.37M
SOXLDirexion Daily Semiconductor Bull 3X Shares
$ 27.30
(3.80%)
107.24M
TSLZT Rex 2X Inverse Tesla Daily Target ETF
$ 2.435
(7.27%)
93.88M
KULRKULR Technology Group Inc
$ 2.885
(28.79%)
75.32M

AEON Discussion

View Posts
glenn1919 glenn1919 2 months ago
AEON............................https://stockcharts.com/h-sc/ui?s=AEON&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 3 months ago
AEON new 52=week low
👍️0
willlbone willlbone 5 months ago
Dilution.
👍️0
glenn1919 glenn1919 5 months ago
AEON.......................https://stockcharts.com/h-sc/ui?s=AEON&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 5 months ago
AEON under $3
👍️0
glenn1919 glenn1919 5 months ago
AEON..............................................https://stockcharts.com/h-sc/ui?s=AEON&p=W&b=5&g=0&id=p86431144783
👍️0
DewDiligence DewDiligence 5 months ago
AEON repositions ABP-450 as_a potential Botox biosimilar:

https://finance.yahoo.com/news/aeon-biopharma-announces-strategic-reprioritization-120000126.html

AEON is nearly insolvent (#msg-174417740), so it’s hard to see how they complete a phase-3 trial to obtain FDA approval using the 351(k) pathway.

This looks like another instance of Zebra’s Law.

Reminder: ABP-450 is the same drug as EOLS’ Jeuveau, sourced from Korea’s Daewoong.
👍️0
Monksdream Monksdream 6 months ago
AEON new 52 week low
👍️0
Monksdream Monksdream 6 months ago
AEON new 52 week low
👍️0
DewDiligence DewDiligence 7 months ago
AEON—>55% workforce reduction—ABP-450 clinical development suspended:

https://finance.yahoo.com/news/aeon-biopharma-announces-strategic-reprioritization-120000294.html Upon securing additional capital, we would be positioned to announce a revised clinical development strategy for our pipeline of ABP-450 programs. AEON is all but insolvent—see #msg-174417740.

Reminder: ABP-450 is the same drug as EOLS’ Jeuveau, sourced from Korea’s Daewoong.
👍️0
DewDiligence DewDiligence 7 months ago
AEON has a liquidity problem—1Q24 results:

https://www.globenewswire.com/news-release/2024/05/14/2881873/0/en/AEON-Biopharma-Reports-First-Quarter-2024-Financial-Results.html

Net current assets at 3/31/24 were negative ($13.5M). Hence, even after accounting for the $15.0M AEON received from its supplier, Daewoong in an Apr 2024 private placement, net current assets as of today are either close to zero or negative.

No CC.
👍️0
DewDiligence DewDiligence 7 months ago
AEON plows on despite setbacks:

https://www.globenewswire.com/news-release/2024/05/09/2878729/0/en/AEON-Biopharma-Provides-Update-on-Development-Pipeline.html
👍️0
Monksdream Monksdream 8 months ago
AEON new 52+ week low
👍️0
DewDiligence DewDiligence 8 months ago
AEON—(-53%)—reports failed phase-2 in migraine prevention:

https://finance.yahoo.com/news/aeon-biopharma-announces-preliminary-top-110000987.html AEON Biopharma…today announced that the preliminary top-line results from its planned interim analysis of the Phase 2 trial with ABP-450 in the preventive treatment for chronic migraine did not meet the primary endpoint. This is AEON’s second phase-2 failure in migraine, having whiffed in a prior phase-2 for treatment (rather than prevention) of episodic migraine (#msg-173058579).

AEON’s ABP-450 is the exact same drug as EOLS’ Jeuveau, sourced from Korea's Daewoong.

AEON’s lead indication had previously been cervical dystonia, but AEON backed off from CD after RVNC reported stellar data in that indication.

Please see #msg-172274907 for related info.
👍️0
DewDiligence DewDiligence 9 months ago
Dilution from the redemption of warrants:

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001837607/000183760724000017/aeon-20240329x8k.htm
👍️0
trglaa trglaa 9 months ago
What happened here today?
👍️0
DewDiligence DewDiligence 9 months ago
AEON 4Q23 financials:

https://www.globenewswire.com/news-release/2024/03/29/2854830/0/en/AEON-Biopharma-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html
👍️0
DewDiligence DewDiligence 9 months ago
AEON updates plans for migraine program:

https://finance.yahoo.com/news/aeon-biopharma-announces-clinical-productive-203000664.html
👍️0
DewDiligence DewDiligence 9 months ago
AEON sells $15M of convertible debt to_supplier, Daewoong:

https://finance.yahoo.com/news/aeon-biopharma-announces-15-million-202900910.html
👍️0
DewDiligence DewDiligence 11 months ago
AEON presents phase-2 data in cervical dystonia:

https://finance.yahoo.com/news/aeon-biopharma-presents-positive-clinical-210500488.html

CD had been AEON’s lead indication for ABP-450, but AEON changed gears and made episodic migraine the lead indication after RVNC reported Daxxify data in CD (https://www.sec.gov/Archives/edgar/data/1837607/000110465923063774/tm2316532d1_ex99-1.htm ). When AEON’s phase-2 in episodic migraine failed in Oct 2023 (#msg-173058579), CD again became the lead indication by default.

The above PR also includes preclinical data for ABP-450 in PTSD (!?).

AEON needs to raise a significant amount of cash to conduct a phase-3 trial in any indication (#msg-173211412).

Reminder: ABP-450, sourced from Korea’s Daewoong, is the exact same toxin as EOLS’ Jeuveau. See #msg-172274907 for background info.
👍️0
DewDiligence DewDiligence 1 year ago
AEON needs to raise cash very soon:

https://www.globenewswire.com/news-release/2023/11/13/2779046/0/en/AEON-Biopharma-Reports-Third-Quarter-2023-Financial-Results.html The Company reported cash, cash equivalents and investments were approximately $16.2 million as of September 30, 2023.

The Company believes its cash, cash equivalents and investments will be sufficient to fund its planned clinical studies, as well as support corporate operations into mid-December 2023. No quarterly CC.
👍️0
DewDiligence DewDiligence 1 year ago
AEON phase-2 trial_in episodic migraine misses_ primary_endpoint:

https://finance.yahoo.com/news/aeon-biopharma-announces-topline-results-200500504.html On the primary endpoint, the topline data showed ABP-450 had a treatment effect with mean reductions in MMD [monthly migraine days] of 4.8 days at the 150U dose (n = 99) and 5.0 days at the 195U dose (n = 108), compared to only 4.2 days in placebo (n = 98) at weeks 21-24, but did not meet statistical significance… Episodic migraine is (was) ABP-450’s lead indication. The lead indication had previously been cervical dystonia, but AEON backed off from CD due, presumably, to RVNC’s stellar dataset in that indication.

AEON’s ABP-450 is the exact same drug as EOLS’ Jeuveau. Please see #msg-172274907 for related info.
👍️0
DewDiligence DewDiligence 1 year ago
AEON's trading liquidity is so low it doesn't take much to move the share price. Today's news was actually minor in the overall scheme of things insofar as AEON has apparently put the brakes on its clinical program in cervical dystonia in order to pursue episodic migraine.
👍️0
trglaa trglaa 1 year ago
Nice run today.
👍️0
DewDiligence DewDiligence 1 year ago
AEON presents phase-2 data in cervical dystonia:

https://finance.yahoo.com/news/aeon-biopharma-presents-positive-results-120000687.html

Note: Episodic migraine, rather than cervical dystonia, is now AEON’s lead indication for ABP-450. This change is presumably due to RVNC’s robust data in cervical dystonia and the recent FDA approval of Daxxify for CD.

See #msg-172274963 for related info.
👍️0
DewDiligence DewDiligence 1 year ago
AEON's initial press release:

https://finance.yahoo.com/news/aeon-biopharma-announces-closing-business-110000037.html
👍️0
TESLA777 TESLA777 1 year ago
$AEON This is the one Im watching/trading tomorrow....GLTY......
👍️0
DewDiligence DewDiligence 1 year ago
AEON’s corporate slide presentation:

https://www.sec.gov/Archives/edgar/data/1837607/000110465923063774/tm2316532d1_ex99-1.htm

Notably, AEON’s lead indication is now episodic migraine. AEON’s lead indication was previously cervical dystonia, so it seems reasonable to surmise that RVNC’s stellar data in CD altered AEON’s plans.
👍️0
DewDiligence DewDiligence 1 year ago
AEON seeks_to_compete_in_the therapeutic—(rather than aesthetic)—market_for botulinum toxin. AEON's botulinum toxin, ABP-450 is the exact same product as EOLS’ Jeuveau, sourced from Korea's Daewoong.
👍️0
DewDiligence DewDiligence 1 year ago
AEON Biopharma begins_trading_7/24/23_under_the_symbol, AEON, following the closing of the SPAC merger with PMGM:

https://finance.yahoo.com/news/priveterra-acquisition-corp-announces-completion-202700149.html
👍️0

Your Recent History

AMEX
AEON
AEON Biopharma
BIT
BB
BB Biotech
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads